Thursday, November 8, 2012
The greater social question
Llewellyn King asks:
These drugs, Ampligen and Retuxin, with their hint of hope in a dark sky, raise a basic societal issue: Is it better for society to pay to make hundreds of thousands of citizens well enough to work, or is the externality of lost work too hard to figure into public health policy and budgeting?
* * *
Dr. Jason estimates the loss to the US economy from CFS is $26B per year. If we could devote just 1% of that ($260M) to CFS research each year, the taxes paid by those who return to the workforce as a result of treatment would quickly return that to the treasury.